Interestingly, phase I studies of anti-CD47 (TTI-621) in 12 PTCL and 29 CTCL patients achieved an overall response rate (ORR) of 18% (2/11) and 21% (6/29), respectively (NCT02663518) [31], with 4 of 5 Sezary Syndrome (SS) patients having a prominent decrease in malignant clones 8 days after infusion [30]. This evidence concerns the gene CD47 and mature T-cell and NK-cell non-Hodgkin lymphoma.